Chester County News and Community Website
NEW HOPE, PA — Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) said the U.S. Food and Drug Administration granted a second Breakthrough Device Designation for its AVIM Therapy, expanding its potential …
Orchestra BioMed Gains Second FDA Breakthrough Designation Read More NEW HOPE, PA — Orchestra BioMed Holdings Inc. (Nasdaq: OBIO) reported its full-year 2025 financial results and said it is advancing two pivotal clinical trials for therapies targeting hypertension and …
Orchestra BioMed Reports 2025 Results, Advances Pivotal Clinical Trials Read More NEW HOPE, PA — Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) announced that company management will participate in two upcoming institutional investor conferences in March, including live presentations and one-on-one meetings …
Orchestra BioMed to Present at Two Healthcare Conferences Read More NEW HOPE, PA — Orchestra BioMed Holdings Inc. (Nasdaq: OBIO) announced that its board compensation committee granted stock options to purchase an aggregate of 120,000 shares of common stock to …
Orchestra BioMed Grants Inducement Stock Options to Nine New Employees Read More NEW HOPE, PA — Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) granted stock options to purchase 151,250 shares of common stock to 12 recently hired employees, the company said following a …
Orchestra BioMed Grants New Hire Stock Options as Clinical Programs Advance Read More NEW HOPE, PA — Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) reported third-quarter financial results and detailed a series of strategic and regulatory milestones that collectively secured more than $147 million …
Orchestra BioMed’s Big Cash Infusion Sets Stage for High-Stakes Cardiology Trials Read More NEW HOPE, PA — Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) announced it will host a business update call on Wednesday, November 12, at 8:00 a.m. ET to discuss a series …
Orchestra BioMed to Deliver Major Business Update Amid Rapid Clinical Momentum Read More NEW HOPE, PA — Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) announced a new agreement with Japan’s Terumo Corporation (TYO: 4543) that grants Terumo a right of first refusal for the …
Orchestra BioMed Secures $30 Million Terumo Deal for Coronary Device Rights Read More NEW HOPE, PA — Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) has begun enrolling patients in the Virtue SAB in the Treatment of Coronary ISR Trial, a U.S. IDE pivotal study …
Orchestra BioMed Kicks Off Pivotal U.S. Trial of Non-Coated Sirolimus Balloon Read More NEW HOPE, PA — Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) announced that new data supporting the potential of Atrioventricular Interval Modulation (AVIM) Therapy in managing hypertensive heart disease, which was …
Orchestra BioMed to Highlight AVIM Therapy’s Potential to Transform Hypertension Care Read More